Nicox initiates study of dual-action glaucoma drug

Nicox S.A. has enrolled the first 10 patients in a phase 2 study of NCX 470, a nitric oxide-donating prostaglandin analog, for the reduction of IOP, according to a press release.

The multicenter, double-masked, parallel group, dose-ranging study will compare the safety and efficacy of NCX 470 against latanoprost 0.005% in 420 adults with open-angle glaucoma or ocular hypertension, the release said.

“NCX 470 is a new chemical entity which uses bimatoprost, a prostaglandin analog, as a scaffold for attaching an NO-donating moiety in order to achieve a dual mechanism of action,” the release stated.

The primary endpoint is mean reduction in diurnal IOP after 4 weeks of treatment.

“Based on our preclinical data, we believe that NCX 470 may provide a clinically meaningful improvement over the current standard of care, and become a first-line therapy for these patients,” Nicox chairman and CEO Michele Garufi said.

Nicox S.A. has enrolled the first 10 patients in a phase 2 study of NCX 470, a nitric oxide-donating prostaglandin analog, for the reduction of IOP, according to a press release.

The multicenter, double-masked, parallel group, dose-ranging study will compare the safety and efficacy of NCX 470 against latanoprost 0.005% in 420 adults with open-angle glaucoma or ocular hypertension, the release said.

“NCX 470 is a new chemical entity which uses bimatoprost, a prostaglandin analog, as a scaffold for attaching an NO-donating moiety in order to achieve a dual mechanism of action,” the release stated.

The primary endpoint is mean reduction in diurnal IOP after 4 weeks of treatment.

“Based on our preclinical data, we believe that NCX 470 may provide a clinically meaningful improvement over the current standard of care, and become a first-line therapy for these patients,” Nicox chairman and CEO Michele Garufi said.